Wěi Li

Research interests

Publications

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00920

• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203690

• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02420-5

• Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer

  Journal of Clinical Investigation · 2020 · https://doi.org/10.1172/jci133264

• ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer

  Cancer Cell · 2019 · https://doi.org/10.1016/j.ccell.2019.01.008

• Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30729-5

• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1706450

• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

  Cancer Cell · 2016 · https://doi.org/10.1016/j.ccell.2016.02.006

• HIF-1α pathway: role, regulation and intervention for cancer therapy

  Acta Pharmaceutica Sinica B · 2015 · https://doi.org/10.1016/j.apsb.2015.05.007

• Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease

  PLoS Genetics · 2014 · https://doi.org/10.1371/journal.pgen.1004123

• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(13)70604-1

• An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

  Pharmaceutical Research · 2012 · https://doi.org/10.1007/s11095-012-0828-z

• Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL

  Journal of Biological Chemistry · 2001 · https://doi.org/10.1074/jbc.m100740200

Current projects

No projects listed.